Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Accelerated approvals hit the target in precision oncology!
We showed that accelerated approvals based on ORR and single arm studies were perfect match for precision oncology.”
Title: Accelerated approvals hit the target in precision oncology
Authors: V. Subbiah, Lori J. Wirth, Razelle Kurzrock, Richard Pazdur, Julia A. Beaver, Harpreet Singh, Gautam U. Mehta
Other articles featuring Dr. Subbiah on OncoDaily.